We are live on ! Find out more
ACOR

Acorda Therapeutics
ACOR

Delisted

ACOR was delisted on the 11th of April, 2024.

Back to rankings

150 hedge funds and large institutions have $1.09B invested in Acorda Therapeutics in 2017 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 55 increasing their positions, 53 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

4% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 53

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

9% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 22

1% less funds holding

Funds holding: 152 → 150 (-2)

13% less capital invested

Capital invested by funds: $1.26B → $1.09B (-$170M)

65% less call options, than puts

Call options by funds: $4.38M | Put options by funds: $12.7M

Holders
150
Holders Change
-2
Holders Change %
-1.32%
% of All Funds
3.4%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
20
Increased
55
Reduced
53
Closed
22
Calls
$4.38M
Puts
$12.7M
Net Calls
-$8.29M
Net Calls Change
-$6.73M

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$10.5M
2
HEC
Hudson Executive Capital
New York
+$10M
3
Norges Bank
Norges Bank
Norway
+$9.65M
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$7.08M
5
State Street
State Street
Massachusetts
+$6.34M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$27.5M
2
RCM
RA Capital Management
Massachusetts
-$21.3M
3
Macquarie Group
Macquarie Group
Australia
-$16.2M
4
PHS
PFM Health Sciences
California
-$14.2M
5
Deutsche Bank
Deutsche Bank
Germany
-$12.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
Prudential Financial
26
Prudential Financial
New Jersey
$5.16M +$1.85M +650 +48%
Two Sigma Advisers
27
Two Sigma Advisers
New York
$4.78M -$1.01M -354 -16%
BBA
28
Baker Bros. Advisors
New York
$4.42M -$7.43M -2,613 -60%
Millennium Management
29
Millennium Management
New York
$4.26M +$4.71M +1,657 New
AIM
30
Alambic Investment Management
California
$4.2M -$992K -349 -18%
T. Rowe Price Associates
31
T. Rowe Price Associates
Maryland
$3.81M -$890K -313 -17%
Deutsche Bank
32
Deutsche Bank
Germany
$3.45M -$12.2M -4,297 -76%
GT
33
Glenmede Trust
Pennsylvania
$3.05M -$2.84K -1 -0.1%
TCIM
34
TIAA CREF Investment Management
New York
$2.88M -$1.71M -601 -35%
PAM
35
Panagora Asset Management
Massachusetts
$2.79M -$5.69K -2 -0.2%
OAM
36
Oxford Asset Management
United Kingdom
$2.62M +$731K +257 +36%
RJA
37
Raymond James & Associates
Florida
$2.6M -$387K -136 -12%
PAMU
38
Pictet Asset Management (UK)
United Kingdom
$2.36M -$313K -110 -11%
RhumbLine Advisers
39
RhumbLine Advisers
Massachusetts
$2.32M +$350K +123 +16%
PPA
40
Parametric Portfolio Associates
Washington
$2.31M +$96.7K +34 +4%
QI
41
QS Investors
New York
$2.27M -$102K -36 -4%
AllianceBernstein
42
AllianceBernstein
Tennessee
$2.16M +$694K +244 +41%
Wells Fargo
43
Wells Fargo
California
$2.05M +$244K +86 +12%
Legal & General Group
44
Legal & General Group
United Kingdom
$2.02M +$105K +37 +5%
GC
45
Guggenheim Capital
Illinois
$1.98M -$591K -208 -21%
MCM
46
Matarin Capital Management
New York
$1.95M +$2.15M +756 New
State of New Jersey Common Pension Fund D
47
State of New Jersey Common Pension Fund D
New Jersey
$1.93M – – –
CS
48
Credit Suisse
Switzerland
$1.92M -$307K -108 -13%
TA
49
Teachers Advisors
New York
$1.9M +$239K +84 +13%
Wellington Management Group
50
Wellington Management Group
Massachusetts
$1.85M -$51.2K -18 -2%
1
2
3 4 5

ACOR Hedge Fund Activity: Q4 2017 in Review

150 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q4 2017, worth a combined $1.09B — down 13% from $1.26B a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of ACOR and 20 opened new positions — a net loss of 2 holders — while 53 trimmed existing stakes and 55 added.

The largest buyer was Morgan Stanley, adding an estimated $10.5M. The largest seller was Fidelity Investments, cutting an estimated $27.5M.

  • 150 institutional investors held Acorda Therapeutics (ACOR) as of Q4 2017, down from 152 in Q3 2017.
  • Funds reported $1.09B of Acorda Therapeutics stock for Q4 2017, down 13% quarter-over-quarter.
  • 20 funds opened new Acorda Therapeutics positions in Q4 2017 and 22 closed out, a net change of -2 holders.
  • The largest Acorda Therapeutics buyer in Q4 2017 was Morgan Stanley, an estimated $10.5M added.
  • The largest Acorda Therapeutics seller in Q4 2017 was Fidelity Investments, an estimated $27.5M sold.

Based on aggregated 13F filings for Q4 2017.